A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
Status:
Completed
Trial end date:
2017-10-25
Target enrollment:
Participant gender:
Summary
Sixty patients with advanced squamous cell carcinomas of the head and neck will be enrolled
in this study. Patients are treated with standard chemoradiation in combination with
concurrent add-on cetuximab. Subsequently patients are randomized to cetuximab consolidation
therapy (three months, Arm A) versus no consolidation therapy (Arm B). The aim of this study
is to investigate if cetuximab consolidation therapy improves the 2-year locoregional control
rate.
- Trial with medicinal product
- Trial with radiotherapy